Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852956 | 0.81 | POLB (0.55) | MAOAMAOBPOLBCTSBALDH1A1 | |
| SCHEMBL223271 | 0.81 | POLB (0.55) | MAOAMAOBPOLBCTSBALDH1A1 | |
| SCHEMBL29900511 | 0.80 | ALDH1A1 (0.60) | MAOAMAOBPOLBCTSBALDH1A1 | |
| SCHEMBL20872955 | 0.80 | MAOA (0.54) | MAOAMAOBPOLBALDH1A1L3MBTL1 | |
| SCHEMBL10470690 | 0.80 | MAOA (0.50) | MAOAMAOBPOLBCTSBALDH1A1 | |
| SCHEMBL23092695 | 0.80 | ALDH1A1 (0.60) | MAOAMAOBPOLBCTSBALDH1A1 | |
| SCHEMBL18864972 | 0.80 | MAOB (0.58) | MAOAMAOBPOLBCTSBALDH1A1 | |
| SCHEMBL22804940 | 0.80 | MAOB (0.58) | MAOAMAOBPOLBALDH1A1L3MBTL1 | |
| SCHEMBL2425637 | 0.80 | MAOB (0.58) | MAOAMAOBPOLBALDH1A1L3MBTL1 | |
| SCHEMBL12777967 | 0.80 | MAOB (0.58) | MAOAMAOBPOLBCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483247-B1 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2009-06-24 | — | — | EP | claimed |
| US-7229993-B2 | Aryl substituted pyrimidines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-06-12 | — | — | US | claimed |
| CN-1646500-A | Aryl substituted pyrimidines and the use thereof | EURO CELTIQUE SA (LU) | 2005-07-27 | — | — | CN | claimed |
| EP-1483247-A2 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2004-12-08 | — | — | EP | claimed |
| US-20030236273-A1 | Aryl substituted pyrimidines and the use thereof | EURO-CELTIQUE S.A. | 2003-12-25 | — | — | US | claimed |
| WO-2003076414-A2 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (US) | 2003-09-18 | — | — | WO | claimed |
| CN-103906518-B | Malignant and non-malignant disease treatment using RAS antagonists | 派西斯治疗有限责任公司 | 2020-03-13 | — | — | CN | disclosed |
| US-9738614-B2 | Malignant and non-malignant disease treatment with Ras antagonists | PISCES THERAPEUTICS, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2763681-B1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | PISCES THERAPEUTICS LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| CN-103709163-B | Xanthine derivative, Preparation Method And The Use | 齐鲁制药有限公司 | 2016-12-21 | — | — | CN | disclosed |
| US-20160207891-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | PISCES THERAPEUTICS, LLC (US) | 2016-07-21 | — | — | US | disclosed |
| US-9309203-B2 | Malignant and non-malignant disease treatment with Ras antagonists | PISCES THERAPEUTICS, LLC (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140249163-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | PICES THERAPEUTICS LLC (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2763681-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | Pisces Therapeutics LLC (US) | 2014-08-13 | — | — | EP | disclosed |
| CN-103906518-A | Malignant and non-malignant disease treatment using RAS antagonists | PISCES THERAPEUTICS LLC | 2014-07-02 | — | — | CN | disclosed |
| CN-103709163-A | Xanthine derivative, preparation method thereof and uses thereof | QILU PHARMACEUTICAL CO LTD | 2014-04-09 | — | — | CN | disclosed |
| WO-2013052765-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | PISCES THERAPEUTICS LLC (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-0915850-A1 | NOVEL CARBOCYCLIC DIARYLMETHYLENE DERIVATIVES, METHODS FOR PREPARING SAME, AND THERAPEUTICAL USES THEREOF | LABORATOIRES UPSA (FR) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998005643-A1 | NOVEL CARBOCYCLIC DIARYLMETHYLENE DERIVATIVES, METHODS FOR PREPARING SAME, AND THERAPEUTICAL USES THEREOF | LABORATOIRES UPSA (FR) | 1998-02-12 | — | — | WO | disclosed |
| US-3954994-A | Intermediates for preparing hipolipemic agents and method of lowering the blood lipid level in mammals with said agents | PFIZER INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249163-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | HRAS, KRAS, NRAS | MAOA 3569/4885MAOB 3225/4885POLB 2087/4885 |
| US-20160207891-A1 | MALIGNANT AND NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | HRAS, KRAS, NRAS | MAOA 3569/4885MAOB 3225/4885POLB 2087/4885 |
| US-20030236273-A1 | Aryl substituted pyrimidines and the use thereof | CACNA1S, CACNA1C, NCS1 | MAOA 1406/4885MAOB 836/4885POLB 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.